Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway

Objective To explore whether dihydroartemisinin (DHA) can block interleukin (IL)-6-induced epithelial–mesenchymal transition (EMT) in laryngeal squamous cell carcinoma (LSCC). Methods The expression of SLUG, signal transducer and activator of transcription 3 (STAT3), and microRNA (miR)-130b-3p was m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yajing Sun, Xiuying Lu, Hui Li, Xiaoming Li
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/cb8a7bb368aa41fc9077f98c5913a329
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb8a7bb368aa41fc9077f98c5913a329
record_format	dspace
spelling	oai:doaj.org-article:cb8a7bb368aa41fc9077f98c5913a3292021-11-11T01:33:21ZDihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway1473-230010.1177/03000605211009494https://doaj.org/article/cb8a7bb368aa41fc9077f98c5913a3292021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211009494https://doaj.org/toc/1473-2300Objective To explore whether dihydroartemisinin (DHA) can block interleukin (IL)-6-induced epithelial–mesenchymal transition (EMT) in laryngeal squamous cell carcinoma (LSCC). Methods The expression of SLUG, signal transducer and activator of transcription 3 (STAT3), and microRNA (miR)-130b-3p was measured. In addition, a dual-luciferase reporter assay was performed to examine the interaction of miR-130b-3p with STAT3. Results We found that IL-6 can promote EMT and invasion in LSCC cells, whereas DHA can inhibit these two processes. However, DHA alone does not influence EMT and cancer invasion. Furthermore, DHA upregulated miR-130b-3p, which can downregulate STAT3 and β-catenin protein expression and decrease the activity of the IL-6/STAT3 signaling pathway. Moreover, we found that miR-130b-3p can target STAT3 directly. Conclusions DHA can block IL-6-triggered EMT and invasion in LSCC, and during these processes, DHA increases miR-130b-3p expression to decrease the activation of the IL-6/STAT3 and β-catenin signaling pathways. These findings may provide new insights into strategies for suppressing and even preventing LSCC metastasis.Yajing SunXiuying LuHui LiXiaoming LiSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Yajing Sun Xiuying Lu Hui Li Xiaoming Li Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
description	Objective To explore whether dihydroartemisinin (DHA) can block interleukin (IL)-6-induced epithelial–mesenchymal transition (EMT) in laryngeal squamous cell carcinoma (LSCC). Methods The expression of SLUG, signal transducer and activator of transcription 3 (STAT3), and microRNA (miR)-130b-3p was measured. In addition, a dual-luciferase reporter assay was performed to examine the interaction of miR-130b-3p with STAT3. Results We found that IL-6 can promote EMT and invasion in LSCC cells, whereas DHA can inhibit these two processes. However, DHA alone does not influence EMT and cancer invasion. Furthermore, DHA upregulated miR-130b-3p, which can downregulate STAT3 and β-catenin protein expression and decrease the activity of the IL-6/STAT3 signaling pathway. Moreover, we found that miR-130b-3p can target STAT3 directly. Conclusions DHA can block IL-6-triggered EMT and invasion in LSCC, and during these processes, DHA increases miR-130b-3p expression to decrease the activation of the IL-6/STAT3 and β-catenin signaling pathways. These findings may provide new insights into strategies for suppressing and even preventing LSCC metastasis.
format	article
author	Yajing Sun Xiuying Lu Hui Li Xiaoming Li
author_facet	Yajing Sun Xiuying Lu Hui Li Xiaoming Li
author_sort	Yajing Sun
title	Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
title_short	Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
title_full	Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
title_fullStr	Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
title_full_unstemmed	Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
title_sort	dihydroartemisinin inhibits il-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the mir-130b-3p/stat3/β-catenin signaling pathway
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/cb8a7bb368aa41fc9077f98c5913a329
work_keys_str_mv	AT yajingsun dihydroartemisinininhibitsil6inducedepithelialmesenchymaltransitioninlaryngealsquamouscellcarcinomaviathemir130b3pstat3bcateninsignalingpathway AT xiuyinglu dihydroartemisinininhibitsil6inducedepithelialmesenchymaltransitioninlaryngealsquamouscellcarcinomaviathemir130b3pstat3bcateninsignalingpathway AT huili dihydroartemisinininhibitsil6inducedepithelialmesenchymaltransitioninlaryngealsquamouscellcarcinomaviathemir130b3pstat3bcateninsignalingpathway AT xiaomingli dihydroartemisinininhibitsil6inducedepithelialmesenchymaltransitioninlaryngealsquamouscellcarcinomaviathemir130b3pstat3bcateninsignalingpathway
_version_	1718439628861603840

Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway

Ejemplares similares